Select your cookie preferences

We use essential cookies and similar tools that are necessary to provide our site and services. We use performance cookies to collect anonymous statistics, so we can understand how customers use our site and make improvements. Essential cookies cannot be deactivated, but you can choose “Customize” or “Decline” to decline performance cookies.

If you agree, AWS and approved third parties will also use cookies to provide useful site features, remember your preferences, and display relevant content, including relevant advertising. To accept or decline all non-essential cookies, choose “Accept” or “Decline.” To make more detailed choices, choose “Customize.”

Sign in
Your Saved List Become a Channel Partner Sell in AWS Marketplace Amazon Web Services Home Help

Anticoagulation Therapy Outcomes

Provided By: John Snow Labs

Anticoagulation Therapy Outcomes

Provided By: John Snow Labs

This data package is about anticoagulant therapy. It includes following datasets: patients with and without hematoma enlargement, chronic care management differences and patient outcomes in anticoagulant clinics, participant characteristics anticoagulants randomized trial, pulmonary embolism thrombolysis treatment and its complications.

Product offers

The following offers are available for this product. Choose an offer to view the pricing and access duration options for the offer. Select an offer and continue to subscribe. Your subscription begins on the date that you accept the offer. Additional taxes or fees might apply.

Public offer

Payment schedule: Upfront payment | Offer auto-renewal: Supported
$0 for 12 months

Overview

Overview

This data package is a collection of numerous studies related to anticoagulation therapy. The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed a study on behalf of IGNITE (Initiative of German Neuro-intensive Trial Engagement). The study investigated the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption. Another study compared outcome for patients using two different mode of reversal treatments: (1) Fresh Frozen Plasma (FFP), and (2) Prothrombin Complex Concentrates (PCC). A research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy. The data were subjected to regression analysis to identify to what extent the differences in patient outcomes are associated with chronic care management activities. Another study was performed to identify the differences in patient outcomes and their relationship with chronic care management of oral anticoagulant. The goal of another study was to perform a systematic review of the literature and determine pre-specified inclusion criteria based on relevant studies, which are as follows: randomized controlled design in patients with PE evaluating thrombolytic therapy as an intervention; a comparator group that included any of the following agents: low-molecular-weight heparin (LMWH), vitamin K antagonist, fondaparinux, or unfractionated heparin; and reporting of mortality outcomes. We did not include trials that compared different thrombolytic agents against one another or different doses of the same thrombolytic drug.


License Information

The use of John Snow Labs datasets is free for personal and research purposes. For commercial use please subscribe to the Data Library on AWS. The subscription will allow you to use all John Snow Labs datasets and data packages for commercial purposes.


Metadata

DescriptionValue
Data Package ComplexitySimple
Available EnrichmentsN/A
KeywordsAnticoagulant Therapy, Hematoma Treatment, Novel Anticoagulants, Chronic Care Model, Chronic Disease Management, Wagner Chronic Care Model, Thrombolytics, Treatment of Pulmonary Embolism, Warfarin Monitoring, Clotting Factors
Other TitlesPatients on Anticoagulant Therapy With and Without Hematoma Enlargement, Chronic Care Anticoagulant Therapy Management, Warfarin Dosage in Anticoagulant Chronic Care Management, Chronic Disease Management and Patient Outcomes, Thrombolysis Treatment for Pulmonary Embolism Complications

Included Datasets

  1. Characteristics of OAC Patients With and Without Hematoma Enlargement

    The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neuro Intensive Trial Engagement) and was published by The Journal of the American Medical Association (JAMA) on February 24, 2015. The study investigated the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption.

  2. Chronic Care Management Differences in Anticoagulant Clinics

    This research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy. The data were subjected to regression analysis to identify to what extent the differences in patient outcomes are associated with chronic care management activities.

  3. Chronic Care Management Patient Outcomes in Anticoagulant Regions

    This research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy (OAT). This study was performed to identify the differences in patient outcomes and their relationship with chronic care management of OAT.

  4. Participant Characteristics Anticoagulants Randomized Trial JAMA

    This clinical investigation that was published in The Journal of the American Medical Association (JAMA) on June 18, 2014, was a collaboration of efforts from PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL since its inception from April 10, 2014.

  5. Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA

    This clinical investigation that was published in The Journal of the American Medical Association (JAMA) on June 18, 2014, was a collaboration of efforts from PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL since its inception from April 10, 2014. The goal of the study was to determine the risks and complications involved with thrombolytic therapy compared with anticoagulation in acute pulmonary embolism.

  6. Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC

    The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neuro Intensive Trial Engagement) and was published by The Journal of the American Medical Association (JAMA) on February 24, 2015. The study compared outcome for patients using two different mode of reversal treatments: (1) Fresh Frozen Plasma (FFP), and (2) Prothrombin Complex Concentrates (PCC).


Data Engineering Overview

We deliver high-quality data
  • Each dataset goes through 3 levels of quality review
    • 2 Manual reviews are done by domain experts
    • Then, an automated set of 60+ validations enforces every datum matches metadata & defined constraints
  • Data is normalized into one unified type system
    • All dates, unites, codes, currencies look the same
    • All null values are normalized to the same value
    • All dataset and field names are SQL and Hive compliant
  • Data and Metadata
    • Data is available in both CSV and Apache Parquet format, optimized for high read performance on distributed Hadoop, Spark & MPP clusters
    • Metadata is provided in the open Frictionless Data standard, and its every field is normalized & validated
  • Data Updates
    • Data updates support replace-on-update: outdated foreign keys are deprecated, not deleted

Our data is curated and enriched by domain experts

Each dataset is manually curated by our team of doctors, pharmacists, public health & medical billing experts:

  • Field names, descriptions, and normalized values are chosen by people who actually understand their meaning
  • Healthcare & life science experts add categories, search keywords, descriptions and more to each dataset
  • Both manual and automated data enrichment supported for clinical codes, providers, drugs, and geo-locations
  • The data is always kept up to date – even when the source requires manual effort to get updates
  • Support for data subscribers is provided directly by the domain experts who curated the data sets
  • Every data source’s license is manually verified to allow for royalty-free commercial use and redistribution.

Need Help?


About Us

John Snow Labs , an AI and NLP for healthcare company, provides state-of-the-art software, models, and data to help healthcare and life science organizations build, deploy, and operate AI projects.

Provided By
Fulfillment Method
AWS Data Exchange

Data dictionaries

A data dictionary is a visual representation of the contents of a data set. The data represented here is for evaluation purposes only and may not accurately represent the actual content of the product.

Field name
Description
Example
Data type
Primary key
Nullable
Max length
Data set
Table name
Table description
Clinical_Characteristics_of_Patients

Description of the characteristics of the patients who participated in the clinical trial.

-
string
-
-
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Criteria_Parameters

Description of the parameters used in the selection of criteria and measurement of the outcomes of the clinical trial.

-
string
-
false
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Patients_With_Hematoma_Enlargement

Description of the number of patients with hematoma enlargement after use of oral anticoagulants.

-
integer
-
-
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Percentage_of_Patients_With_Hematoma_Enlargement

Description of the percentage of patients with hematoma enlargement after use of oral anticoagulants.

-
numeric
-
-
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Standard_Deviation_Interquartile_Range_of_Variables_With_Hematoma

Description of either standard deviations or interquartile range of the variables in relation to the results according to the parameters of the clinical trial.

-
string
-
-
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Patients_Without_Hematoma_Enlargement

Description of the number of patients without hematoma enlargement after use of oral anticoagulants.

-
integer
-
-
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Percentage_of_Patients_Without_Hematoma_Enlargement

Description of the percentage of patients without hematoma enlargement after use of oral anticoagulants.

-
numeric
-
-
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Standard_Deviation_Interquartile_Range_of_Variables_Without_Hematoma

Description of either standard deviations or interquartile range of the variables in relation to the results according to the parameters of the clinical trial.

-
string
-
-
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Probability

Description of effectiveness of the results of the clinical trial based on the hypothesis of the study.

0.08

string
-
-
-
Characteristics of OAC Patients With and Without Hematoma Enlargement
characteristics_of_oac_patients_with_and_without_hematoma_enlargement
Chronic_Care_Management_Elements

Description of the components of the Chronic Care Management used in different Dutch Anticoagulant Clinic (AC) regions.

-
string
-
-
-
Chronic Care Management Differences in Anticoagulant Clinics
chronic_care_management_differences_in_anticoagulant_clinics

Data sets (6)

You will receive access to the following data sets

Revision access rules
All historical revisions | All future revisions
Name
Type
Data dictionary
AWS Region
Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC
Included
US East (N. Virginia)
Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA
Included
US East (N. Virginia)
Participant Characteristics Anticoagulants Randomized Trial JAMA
Included
US East (N. Virginia)
Chronic Care Management Patient Outcomes in Anticoagulant Regions
Included
US East (N. Virginia)
Chronic Care Management Differences in Anticoagulant Clinics
Included
US East (N. Virginia)
Characteristics of OAC Patients With and Without Hematoma Enlargement
Included
US East (N. Virginia)

Data dictionaries and samples

Sample data is for evaluation purposes only and may not accurately represent the actual content of the product.

Name
Resource
File type
File size
Description
Characteristics of OAC Patients With and Without Hematoma Enlargement
Data set
-
-
-
Data dictionary
Data dictionary
text/csv
-
data_preview.csv
Sample
text/csv
Preview of Characteristics of OAC Patients With and Without Hematoma Enlargement dataset
Chronic Care Management Differences in Anticoagulant Clinics
Data set
-
-
-
Chronic Care Management Patient Outcomes in Anticoagulant Regions
Data set
-
-
-
Participant Characteristics Anticoagulants Randomized Trial JAMA
Data set
-
-
-
Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA
Data set
-
-
-
Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC
Data set
-
-
-

Usage information

By subscribing to this product, you agree that your use of this product is subject to the provider's offer terms including pricing information and Data Subscription Agreement . Your use of AWS services remains subject to the AWS Customer Agreement  or other agreement with AWS governing your use of such services.

Support information

Support contact email address
Refund policy
“No refunds offered. For any questions email us at info@johnsnowlabs.com”
General AWS Data Exchange support